Patents Assigned to AERase, Inc.
  • Method and composition for treating arginase 1 deficiency
    Patent number: 11717562
    Abstract: A method and composition to treat a subject with arginase 1 (ARG1) deficiency (ARG1-D) and to rapidly reduce the levels of at least one of arginine and/or a guanidino compound in the subject.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: August 8, 2023
    Assignee: AERase, Inc.
    Inventors: Scott W. Rowlinson, Anthony G. Quinn, Ann Lowe, David Lowe
  • Compositions and methods for treating cancer with arginine depletion and immuno oncology agents
    Patent number: 10729752
    Abstract: Methods of treating tumors or cancer include administration of an arginine depleting enzyme and an immune-oncology agent.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: August 4, 2020
    Assignee: AERASE, INC.
    Inventors: David Lowe, Scott W. Rowlinson, Susan Alters, Giulia Agnello
  • METHOD AND COMPOSITION FOR TREATING ARGINASE 1 DEFICIENCY
    Publication number: 20190167770
    Abstract: A method and composition to treat a subject with arginase 1 (ARG1) deficiency (ARG1-D) and to rapidly reduce the levels of at least one of arginine and/or a guanidino compound in the subject.
    Type: Application
    Filed: December 5, 2018
    Publication date: June 6, 2019
    Applicant: AERase, Inc.
    Inventors: Scott W. ROWLINSON, Anthony G. QUINN
  • COMPOSITIONS OF ENGINEERED HUMAN ARGINASES AND METHODS FOR TREATING CANCER
    Publication number: 20190000939
    Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.
    Type: Application
    Filed: July 16, 2018
    Publication date: January 3, 2019
    Applicant: AERASE, Inc.
    Inventors: George Georgiou, Everett Stone
  • Compositions of engineered human arginases and methods for treating cancer
    Patent number: 10098933
    Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: October 16, 2018
    Assignee: AERase, Inc.
    Inventors: George Georgiou, Everett Stone
  • Compositions of engineered human arginases and methods for treating cancer
    Patent number: 9050340
    Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: June 9, 2015
    Assignee: AERase, Inc.
    Inventors: George Georgiou, Everett Stone
  • COMPOSITIONS OF ENGINEERED HUMAN ARGINASES AND METHODS FOR TREATING CANCER
    Publication number: 20140242060
    Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.
    Type: Application
    Filed: May 12, 2014
    Publication date: August 28, 2014
    Applicant: AERASE, INC.
    Inventors: George GEORGIOU, Everett STONE
  • Methods for purifying pegylated arginase
    Patent number: 8679479
    Abstract: Methods and composition for generation of arginase variants with high serum persistence are provided. For example, in certain aspects methods for purifying pegylated arginase are described. Furthermore, the invention provides stabilized arginase multimers or pharmaceutical composition thereof.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: March 25, 2014
    Assignee: AERase, Inc.
    Inventors: George Georgiou, Everett Stone
  • Compositions of engineered human arginases and methods for treating cancer
    Patent number: RE46423
    Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: June 6, 2017
    Assignee: AERASE, INC.
    Inventors: George Georgiou, Everett Stone